Volume 66, Issue 5, November 2024

Pulmonary anatomical segmentectomy procedures have gained increasing relevance in recent years.

Adenocarcinoma is the largest subset of lung cancer worldwide [1].

Pectus excavatum, the most common congenital chest wall deformity, can be surgically corrected by the minimally invasive Nuss procedure (i.e. minimally invasive repair of pectus excavatum or MIRPE) [1–3].

Early-stage non-small cell lung cancer (NSCLC) has an 80% 5-year overall survival (OS) rate, and surgery remains the standard treatment.

Pectus excavatum (PE) is a congenital deformity of the anterior chest wall, with a prevalence of at least 1 per 1000 people [1].

Anatomic lobe resection has been standard surgical treatment for early stage non-small-cell lung cancer (NSCLC) [1, 2].

There has been an increase in paediatric heart transplants (HTs) since 2010 [1], and there has been an active effort to improve outcomes.

Right ventricular outflow tract (RVOT) dysfunction is a common late complication following tetralogy of Fallot (TOF) repair.

In patients with obstructive coronary artery disease (CAD), myocardial revascularization—either by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)—may offer additional clinical benefits on top of aggressive medical therapy in specific clinical settings and anatomical subsets [1, 2].

In recent years, there has been a rise in the proportion of patients implanted with a left ventricular assist device (LVAD) as destination therapy [1, 2], along with improved survival rates post-LVAD implantation [2].

Prosthetic valve thrombosis is a rare event in routine valve surgery.

The standard procedure for treating infected native aortic arch and arch graft infection is resection of the infected native aortic arch/arch graft, debridement of the surrounding tissue, in situ graft replacement and tissue filling [1].

Total arch replacement (TAR) with a frozen elephant trunk (FET) has become increasingly common for treating acute type A aortic dissection (AAD) because of its effective outcomes in postoperative aortic remodelling (AR) [1–3].

The extent of the initial aortic arch repair in the setting of acute aortic dissection (AAD) remains controversial and significantly influences the requirement for future reintervention [1, 2].

Aortic intramural haematoma (IMH), characterized by haemorrhage within the aortic wall media, accounts for 26–44% of acute aortic syndromes in Asian populations [1].

The frozen elephant trunk (FET) is a hybrid prosthesis consisting of a woven aortic arch graft and an aortic endovascular stent graft.

Aortic intramural haematoma (IMH) is an important acute aortic syndrome that presents with symptoms similar to those of classic aortic dissection [1].

Ascending aortic replacement ideally involving hemiarch replacement remains the established treatment of choice for patients presenting with acute type A aortic dissection [1].

According to the current international guidelines, transcatheter aortic valve implantation (TAVI) is the recommended option for treating patients with symptomatic and severe aortic valve stenosis (AS) in older patients (≥75 years) and at high-risk or anatomically unsuitable for surgical aortic valve replacement (SAVR).

Open total arch repair (OAR) for aortic arch disease has evolved over the last 2 decades [1–3].

Fenestrated/branched endovascular aneurysm repair (F/B-EVAR) is an established technique to treat thoracoabdominal aneurysm (TAAAs) with reliable early and mid-term results in anatomically selected high-risk patients [1–3].

Despite the evolution of endovascular technology [1], open repair remains the gold standard for treating complex aortic aneurysms (CAAs), including pararenal aortic aneurysms (PRAAs) and thoracoabdominal aortic aneurysms (TAAAs) [2, 3].

Hypertrophic cardiomyopathy (HCM) is a relatively common genetic cardiovascular disease, with a prevalence of approximately 0.2% to 0.5% in the general population [1].

The Synergy between percutaneous coronary intervention (PCI) with Taxus and Cardiac Surgery Extended (SYNTAXES) trial is the extended 10-year follow-up of the SYNTAX trial [1].

Severe tricuspid regurgitation (TR) is associated with significant mortality and morbidity [1–3], leading to progressive right ventricular (RV) dilatation and dysfunction, right heart failure and ultimately end-organ damage [4].

Baseline renal dysfunction adversely affects the short- and long-term outcomes following heart valve surgery [1–3].

Tricuspid regurgitation (TR) frequently accompanies degenerative mitral valve disease, increasing the risk of mortality, heart failure and reduced functional capacity [1, 2].